Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CCCC

C4 Therapeutics Inc

Dec 06 • 04:00PM ET

1.21

Dollar change -0.27
Percentage change -18.24	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.75	Insider Own	14.94%	Shs Outstand	48.97M	Perf Week	-19.87%
Market Cap	59.63M	Forward P/E	-	EPS next Y	-2.53	Insider Trans	0.00%	Shs Float	41.92M	Perf Month	-33.15%
Income	-134.92M	PEG	-	EPS next Q	-0.67	Inst Own	73.66%	Short Float / Ratio	4.66% / 4.07	Perf Quarter	-48.07%
Sales	20.35M	P/S	2.93	EPS this Y	-1.05%	Inst Trans	-2.11%	Short Interest	1.95M	Perf Half Y	-66.48%
Book/sh	4.39	P/B	0.28	EPS next Y	4.33%	ROA	-33.97%	Target Price	17.00	Perf Year	-85.39%
Cash/sh	4.39	P/C	0.28	EPS next 5Y	22.30%	ROE	-50.51%	52W Range	1.23 - 9.41	Perf YTD	-79.49%
Dividend	-	P/FCF	-	EPS past 5Y	-46.29%	ROI	-47.66%	52W High	-87.14%	Beta	2.20
Dividend %	-	Quick Ratio	7.39	Sales past 5Y	17.88%	Gross Margin	60.35%	52W Low	-1.63%	ATR	0.18
Employees	146	Current Ratio	7.39	Sales Q/Q	63.93%	Oper. Margin	-687.49%	RSI (14)	32.43	Volatility	16.51% 11.20%
Optionable	Yes	Debt/Eq	0.33	EPS Q/Q	15.89%	Profit Margin	-663.05%	Rel Volume	9.02	Prev Close	1.48
Shortable	Yes	LT Debt/Eq	0.31	Earnings	Nov 01 BMO	Payout	-	Avg Volume	479.84K	Price	1.21
Recom	2.00	SMA20	-27.11%	SMA50	-27.85%	SMA200	-59.46%	Volume	4,329,036	Change	-18.24%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral	$12 → $10
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight	$15 → $5
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral	$22 → $15
Oct-11-22	Initiated	Morgan Stanley	Underweight	$6
Apr-28-22	Initiated	Credit Suisse	Underperform	$10
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$46 → $15
Mar-10-22	Initiated	JP Morgan	Overweight	$43
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$57
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$25
Nov-23-21	Initiated	BofA Securities	Buy	$54
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20
Sep-30-21	Initiated	Stifel	Hold	$45
Jun-04-21	Initiated	H.C. Wainwright	Buy	$63
Mar-31-21	Initiated	BMO Capital Markets	Outperform	$55
Oct-28-20	Initiated	UBS	Buy	$44
Oct-27-20	Initiated	Jefferies	Buy	$34
Oct-27-20	Initiated	BMO Capital Markets	Outperform	$33

Show Previous Ratings

Nov-28-23 07:00AM	C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Nov-20-23 07:00AM	C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment (GlobeNewswire) -6.63%
Nov-13-23 09:55AM	Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom Fishing (Zacks)
Nov-01-23 11:03AM	C4 Therapeutics discontinues cancer program, waits for Betta payment (FierceBiotech.com) -11.41%
09:40AM	C4 Therapeutics Inc (CCCC) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com)
07:00AM	Loading…
07:00AM	C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-11-23 07:00AM	C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC Degrader in Development for Multiple Myeloma and Non-Hodgkin's Lymphoma (GlobeNewswire)
Sep-05-23 04:01PM	C4 Therapeutics Announces Chief Financial Officer Succession (GlobeNewswire) -7.29%
Aug-28-23 06:30PM	12 Best High Risk Penny Stocks to Buy Now (Insider Monkey)
Aug-08-23 08:40AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-04-23 06:58AM	With 64% institutional ownership, C4 Therapeutics, Inc. (NASDAQ:CCCC) is a favorite amongst the big guns (Simply Wall St.)
Jul-17-23 07:00AM	C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-23 07:00AM	C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer (GlobeNewswire) +17.31%
Jun-20-23 07:00AM	C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer (GlobeNewswire) -7.72%
07:00AM	Loading…
May-30-23 07:00AM	C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC (GlobeNewswire) +8.77%
May-14-23 08:06AM	Broker Revenue Forecasts For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher (Simply Wall St.)
May-04-23 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-19-23 07:00AM	C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days (GlobeNewswire)
Apr-11-23 09:35AM	Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC) (Zacks)
Mar-23-23 07:39AM	Insiders who bought this year lost US$59k as C4 Therapeutics, Inc. (NASDAQ:CCCC) sheds US$27m in value (Simply Wall St.)
Feb-24-23 05:38AM	C4 Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.) -11.46%
Feb-23-23 08:35AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-08-23 07:00AM	C4 Therapeutics to Present at Two Virtual February 2023 Conferences (GlobeNewswire) -5.86%
Jan-30-23 07:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC Degrader, in BRAF V600 Mutant Solid Tumors (GlobeNewswire)
Jan-09-23 07:00AM	C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines (GlobeNewswire) +6.40%
Jan-05-23 06:15PM	C4 Therapeutics, Inc. (CCCC) Dips More Than Broader Markets: What You Should Know (Zacks)
Jan-04-23 09:40AM	Are Medical Stocks Lagging AMN Healthcare Services (AMN) This Year? (Zacks)
07:00AM	Loading…
Jan-03-23 07:00AM	C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.14%
Nov-13-22 07:13AM	The past year for C4 Therapeutics (NASDAQ:CCCC) investors has not been profitable (Simply Wall St.)
Nov-08-22 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet (Zacks)
Nov-03-22 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-02-22 10:01AM	C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.27%
Oct-03-22 09:02AM	One C4 Therapeutics, Inc. (NASDAQ:CCCC) insider upped their stake in the previous year (Simply Wall St.)
Sep-29-22 07:00AM	C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC Degrader, in BRAF-V600 Mutant Solid Cancers (GlobeNewswire) -5.01%
Sep-26-22 07:00AM	C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022 (GlobeNewswire)
Sep-06-22 08:22AM	With 63% ownership of the shares, C4 Therapeutics, Inc. (NASDAQ:CCCC) is heavily dominated by institutional owners (Simply Wall St.)
Aug-10-22 06:05AM	Growth Investors: Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 16% (Simply Wall St.)
Aug-07-22 08:21AM	Analysts Are Upgrading C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its Latest Results (Simply Wall St.)
Aug-04-22 09:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.95%
08:00AM	C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-22 08:00AM	C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors (GlobeNewswire) +6.01%
May-16-22 08:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors (GlobeNewswire) -6.15%
May-05-22 09:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-08-22 02:15PM	C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial (Benzinga) -50.57%
01:00PM	C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader (GlobeNewswire)
10:05AM	Investors one-year losses grow to 32% as the stock sheds US$66m this past week (Simply Wall St.)
Mar-17-22 11:44AM	J.P. Morgan Says Theres Room for Over 80% Gains in These 2 Stocks (TipRanks) +5.92%
Mar-16-22 04:05PM	C4 Therapeutics Appoints Utpal Koppikar to Board of Directors (GlobeNewswire) +5.30%
Mar-09-22 08:00AM	C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma (GlobeNewswire) +15.29%
Mar-08-22 04:30PM	C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Feb-24-22 07:00AM	C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights (GlobeNewswire) +13.96%
Feb-07-22 04:45AM	What Is The Ownership Structure Like For C4 Therapeutics, Inc. (NASDAQ:CCCC)? (Simply Wall St.)
Jan-12-22 11:09AM	Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy? (Insider Monkey)
Jan-10-22 07:00AM	C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio (GlobeNewswire) +8.52%
Jan-03-22 07:00AM	C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-21 12:00PM	What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock (Zacks)
Dec-17-21 08:00AM	C4 Therapeutics Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-01-21 07:28AM	C4 Therapeutics (CCCC) Sees Hammer Chart Pattern: Time to Buy? (Zacks) -7.35%
Nov-22-21 12:00PM	C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Nov-10-21 04:01PM	C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results (GlobeNewswire)
08:34AM	Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season (Zacks)
Oct-26-21 10:41AM	Hedge Funds Are Piling Into C4 Therapeutics, Inc. (CCCC) (Insider Monkey)
Oct-09-21 09:14AM	C4 Therapeutics (NASDAQ:CCCC) pulls back 8.2% this week, but still delivers shareholders notable 85% return over 1 year (Simply Wall St.)
Sep-17-21 10:27AM	Director Of C4 Therapeutics Sold $3.98 Million In Stock (Benzinga)
Aug-11-21 04:02PM	C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results (GlobeNewswire)
04:01PM	C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma (GlobeNewswire)
Aug-10-21 01:31AM	Is C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Jul-21-21 04:24AM	Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy Now? (Insider Monkey)
Jul-19-21 01:44PM	C4 Therapeutics Stock Enters Leadership Territory (Investor's Business Daily)
Jun-21-21 04:01PM	C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
08:00AM	C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma (GlobeNewswire)
Jun-16-21 07:51PM	C4 Therapeutics Announces Pricing of Public Offering (GlobeNewswire)
Jun-14-21 04:12PM	C4 Therapeutics Launches Proposed Public Offering (GlobeNewswire)
08:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies (GlobeNewswire)
Jun-07-21 07:00AM	C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation (GlobeNewswire) +6.17%
May-26-21 07:00AM	C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies (GlobeNewswire) +7.61%
May-20-21 04:01PM	C4 Therapeutics Appoints Lauren White as Chief Financial Officer (GlobeNewswire)
May-13-21 04:01PM	C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results (GlobeNewswire)
May-12-21 07:00AM	C4 Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-21 03:53AM	Did C4 Therapeutics, Inc. (NASDAQ:CCCC) Insiders Buy Up More Shares? (Simply Wall St.)
Apr-10-21 03:05PM	C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021 (GlobeNewswire)
Mar-10-21 04:41PM	C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-02-21 11:50PM	How Much Of C4 Therapeutics, Inc. (NASDAQ:CCCC) Do Insiders Own? (Simply Wall St.)
Feb-24-21 07:00AM	C4 Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-11-21 07:00AM	C4 Therapeutics to Participate in BMO BioPharma Spotlight Series (GlobeNewswire)
Jan-19-21 07:00AM	C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies (GlobeNewswire)
Jan-07-21 07:00AM	C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-21 07:00AM	C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 (GlobeNewswire)
Dec-17-20 07:00AM	C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Nov-25-20 07:00AM	C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx (GlobeNewswire)
Nov-13-20 07:00AM	C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference (GlobeNewswire)
Nov-12-20 04:05PM	C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results (GlobeNewswire)
Oct-23-20 05:54PM	Shattuck Labs, C4 Therapeutics See Activist Actions (Barrons.com)
Oct-14-20 07:30AM	C4 Therapeutics to Present at the 3rd Annual Targeted Protein Degradation Summit (GlobeNewswire)
Oct-06-20 04:05PM	C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Koppikar Utpal	Director	Feb 08	Buy	5.60	5,667	31,735	5,667	Feb 10 04:27 PM
Anderson Kenneth Carl	Director	Jan 06	Option Exercise	3.90	712	2,777	95,128	Jan 06 04:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CCCC

C4 Therapeutics Inc

Upgrade your FINVIZ experience